Estónsko - estónčina - Ravimiamet

novartis baltics sia - deksametasoon+tobramütsiin - silmatilgad, suspensioon - 1mg+3mg 1ml 5ml 1tk

Estónsko - estónčina - Ravimiamet

sandoz pharmaceuticals d.d. - formoterool - inhalatsioonipulber kõvakapslis - 12mcg 30tk

Estónsko - estónčina - Ravimiamet

novartis baltics sia - budesoniid - inhalatsioonipulber kõvakapslis - 200mcg 60tk

Estónsko - estónčina - Ravimiamet

novartis baltics sia - hüdrokortisoon+tsiprofloksatsiin - kõrvatilgad, suspensioon - 10mg+2mg 1ml 10ml 1tk

Estónsko - estónčina - Ravimiamet

novartis baltics sia - oktreotiid - süstesuspensiooni pulber ja lahusti - 10mg 3tk; 10mg 1tk

Estónsko - estónčina - Ravimiamet

novartis baltics sia - tsüklosporiin - pehmekapsel - 50mg 50tk

Európska únia - estónčina - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - ravimid hingamisteede obstruktiivsete haiguste, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Európska únia - estónčina - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Európska únia - estónčina - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - ravimid hingamisteede obstruktiivsete haiguste, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Európska únia - estónčina - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - sclerosis multiplex, relapsing-remitting - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.